


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
GPCR
Structure Therapeutics In
$66.74
GPCR Price Performance
$33.9 (+96.87%)
$20.91 (+219.18%)
$19 (+251.26%)
$19 (+251.26%)
GPCR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

GPCR overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
GPCR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
GPCR Street Sentiment is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels
Login to displayVKTX
37.28
-1.84%
PFE
25.33
-1.78%
NVO
46.36
-0.88%
LLY
982.22
-1.53%
What is GPCR current stock price?
What are GPCR stock strengths?
What is GPCR Risk Level?
What is GPCR market cap and volume?
What is GPCR current Stock IQ?
Should I buy GPCR stock right now?
Is GPCR a Strong Buy right now?
What does a 'Strong Buy' rating mean for GPCR?
What does a 'Strong Sell' rating mean for GPCR?
What factors influence GPCR's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-7.21%
-1.78%
-1.33%
-5.70%
-8.05%
GPCR
Structure Therapeutics In
Current Price
$66.74
Stock Insights
Not Enough Information
Linked to GPCR
VKTX
37.28
-1.84%
PFE
25.33
-1.78%
NVO
46.36
-0.88%
LLY
982.22
-1.53%

GPCR Price Performance
$33.9 (+96.87%)
$20.91 (+219.18%)
$19 (+251.26%)
$19 (+251.26%)
GPCR Analysts Opinion
GPCR Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Rating
Rating
Momentum
Momentum

Has been gaining momentum
Activity
Activity
Future
Future
![]()
GPCR Analysts opinion is negative and it remained unchanged from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential
GPCR Street Sentiment is extremely bullish and have positive views on the near-term outlook
GPCR has Low risk level based on volatility, sector strength, volume, investor confidence, and outlook.
Click here to check what is your level of risk
Risks Indicators

High volatilty

Average key support and resistance price levels
GPCR Stock IQ
GPCR Latest Analysis
Structure Therapeutics (GPCR) Hits 52-Week High on Weight Loss Treatment Trial. We recently published 10 Stocks Standing Tall Amid Market Fall. 6 Hit Record Highs. Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the best performers on Monday. Structure Therapeutics soared to a new 52-week high on Monday after announcing stellar topline results from its ongoing clinical program to test the efficacy of its therapy candidate aleniglipron [….]
Today
GPCR Stock Soars 102% on Strong Phase II Obesity Data for Aleniglipron. Structure Therapeutics jumps after phase II data show aleniglipron delivering strong durable weight-loss results across multiple studies.
Today
In The Uber Biotech Market Is Structure The Next Metsera?. In a post-Metsera world Structure Therapeutics could be the next big takeover candidate analysts said Tuesday.The post In The '.Uber '. Biotech Market Is Structure The Next Metsera? appeared first on Investor'.s Business Daily.
Today
Structure Therapeutics Inc. (GPCR) Discusses Topline Results from ACCESS Program of Oral Small Molecule GLP-1 Receptor Agonist Transcript.
Mon Dec 8, 2025
Structure Therapeutics announces proposed $500 million public offering.
Mon Dec 8, 2025
Crude Oil Falls Over 1%. Structure Therapeutics Shares Jump. United States stocks traded lower midway through trading with the Dow Jones index falling more than 200 points on Monday.The Dow traded down 0.46% to 47733.58 while the NASDAQ fell 0.32% to 23501.92. The S&.P 500 also fell dropping 0.46% to 6838.69.Check This Out: Information technology shares jumped by 0.6% on Monday.In trading on Monday communication services stocks fell by 2.1%.The one-year-ahead median inflation expectations in
Mon Dec 8, 2025
Structure Therapeutics surges on phase 2 data for GLP-1 pill aleniglipron.
Mon Dec 8, 2025
Structure Therapeutics Soars. CEO Says It Could Have Best-In-Class Weight-Loss Drug. Structure Therapeutics said Monday patients who took its obesity treatment lost up to 15.3% more body weight than placebo recipients.The post Structure Therapeutics Soars. CEO Says It Could Have '.Best-In-Class'. Weight-Loss Drug appeared first on Investor'.s Business Daily.
Mon Dec 8, 2025
Structure Therapeutics To Report Key Phase 2 Data For GLP-1 Agonist Aleniglipron In Obesity Today . (RTTNews) - Structure Therapeutics (GPCR) announced that it will present topline results from its pivotal ACCESS clinical program evaluating Aleniglipron for the treatment of obesity on December 8 2025.
Mon Dec 8, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GPCR Stock trends
GPCR Stock performance
GPCR Stock analysis
GPCR investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.